Collectively, these results suggested that early diagnosis with iodide-loaded (myo)fibroblast-targeted NPs provides a key time window for effective therapy of PF, and that the dual activation of Nrf2 and PPARγ signaling accelerated fibrosis resolution and had a synergistic therapeutic effect on bleomycin-induced PF. The gene discussed is NFE2L2; the disease is pemphigus foliaceus.